JP2019094313A - Bloating improving composition and method for screening material or composition having bloating improvement action - Google Patents

Abstract

To provide a bloating improving composition and a method for screening a material or composition having a bloating improvement action.SOLUTION: The present invention provides a composition for oral administration containing an antifoaming agent, a Cassia seed and a probiotic. The present invention provides a method for screening a material or composition having a bloating improvement action, including the steps of: administering a test material or composition to an experimental animal that has taken feed containing (1) cellulose, (2) a polysaccharide having two or more monosaccharides (excluding cellulose), and (3) an amylase inhibitor or α-glucosidase inhibitor, where the component (2) contained in high concentrations; and measuring the intestinal gas volume and/or intestinal volume of the experimental animal to which the test material or composition has been administered.SELECTED DRAWING: Figure 6

Description

  The present invention relates to a composition for improving abdominal bloating and a method of screening a substance or composition having a bloating effect.

  A degassing composition containing a digestive enzyme as an active ingredient is known (Patent Document 1).

  However, it is not known that the composition for oral administration containing an antifoamer, ketchmex and probiotics, and that it is useful for improving abdominal bloating. Furthermore, there is no report on a model animal exhibiting abdominal distension.

Japanese Patent Application Laid-Open No. 11-180890

  An object of the present invention is to provide a composition for improving abdominal bloating and a method of screening a substance or composition having a bloating effect.

  As a result of intensive studies to solve the above problems, the present inventors have found that a composition containing them can improve the feeling of abdominal distension by combining an antifoaming agent, a kestmeist and a probiotics. Based on this finding, further studies and further studies have been conducted to complete the present invention.

That is, the present invention relates to the following inventions.
[1] A composition for oral administration containing an antifoaming agent, ketchmex and probiotics.
[2] The composition according to the above [1], wherein the probiotics are lactic acid bacteria and / or bifidobacteria.
[3] The composition according to the above-mentioned [1] or [2], which is used for improving abdominal fullness.
[4] (1) cellulose, (2) polysaccharides having two or more monosaccharides (excluding cellulose), and (3) amylase inhibitor or α-glucosidase inhibitor, the component (2) is high Feed contained in the concentration.
[5] An experimental animal which receives the feed described in [4] above.
[6] A step of administering a test substance or composition to the experimental animal described in the above [5], and measuring the amount of gas and / or intestinal volume in the intestinal tract of the experimental animal to which the test substance or composition has been administered A method of screening for a substance or composition having a bloating effect, which comprises the steps of

  The present invention can provide a composition for improving abdominal bloating and a method of screening a substance or composition having a bloating effect. In addition, the present invention can provide an experimental animal used in the method of screening and a feed to be fed to the experimental animal.

FIG. 1 shows the difference in cecal gas volume between the normal group and the cecal gas production model animal (n = 6, mean ± standard error, * p <0.05 vs. normal group). FIG. 2 shows the difference in relative cecal volume between the normal group and the cecal gas production model animal (n = 6, mean ± standard error, * p <0.05 vs. normal group). FIG. 3 shows the effect of antifoaming agent alone on cecal gas volume in a cecal gas production model animal (n = 6, mean ± standard error). FIG. 4 shows the effect of Ketchaishi alone on cecal gas volume in a cecal gas production model animal (n = 6, mean ± standard error). FIG. 5 shows the effect of probiotics alone on cecal gas volume in a cecal gas production model animal (n = 6, mean ± standard error). FIG. 6 shows the effect of the combination of an antifoaming agent, ketchumishi and probiotics on cecal gas volume in a cecal gas production model animal (n = 6, mean ± standard error, * p <0.05 vs. Control group). FIG. 7 shows the effect of antifoaming agent alone on cecal relative volume in a cecal gas production model animal (n = 6, mean ± standard error). FIG. 8 shows the effect of Ketchaishi alone on cecal relative volume in a cecal gas production model animal (n = 6, mean ± standard error). FIG. 9 shows the effect of probiotics alone on cecal relative volume in a cecal gas production model animal (n = 6, mean ± standard error). FIG. 10 shows the effect of the combination of an antifoaming agent, ketchmee and probiotics on cecal relative volume in a cecal gas production model animal (n = 6, mean ± standard error, * p <0.05 vs. control) group).

1. Composition The present disclosure includes a composition for oral administration containing a defoaming agent, Kumquat and probiotics (hereinafter also referred to as the composition of the present invention).

Composition-containing component 1: Antifoaming agent In the composition of the present invention, the antifoaming agent has an action to prevent the liquid from foaming or an action to eliminate the existing foam, in particular Examples include, but are not limited to, dimethyl silicones such as dimethicone or simethicone, silicones such as methylphenyl silicone and methyl vinyl silicone; and alcohols such as hydrous ethanol, ethanol and octoxynol.
These may be used singly or in combination of two or more. A commercial item can be used for these.
The content of the antifoaming agent relative to the entire composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, but it is usually 0.1 to 90% by mass, preferably 1 to 70% by mass. Preferably it is 1-20 mass%. The daily amount of the antifoaming agent is usually 36 to 180 mg, preferably 90 to 180 mg, and particularly preferably 120 to 180 mg.

Composition-containing ingredient 2: Ketchmeishetsumeishi (Deceiiko) is usually a seed of the leguminous Ebisgusa (scientific name: Senna obtusifolia). The nutweeds can include anthraquinones, naphthalene derivatives or anthracene derivatives and the like. In the present disclosure, in addition to the raw material as collected, the ketsumeishi may be a processed material such as a dried product, a cut product or a powder thereof, a squeezed juice, or an extract. The extract is not particularly limited as long as the component contained in Ketsumeishi is extracted, but it is not particularly limited. For example, Ketchmeishi, its dried product, a cut product or a powder thereof may be water (hot water or hot water), ethanol, isopropanol, An extract obtained by extracting for about 1 minute to 12 hours at room temperature or under heating with a solvent such as ethyl acetate, acetone, or a mixture thereof (eg, 20 to 80 vol% aqueous ethanol), a diluted solution thereof or the like Concentrates, or their dried products and their powders can be mentioned. After the extraction operation, it is preferable to carry out a solid-liquid separation operation such as filtration or centrifugation to remove insoluble solids.

Preferably, the dried product of ketsumeishi is ground, crushed or shredded by a grinder such as a raw material hopper, grinder, classifier or product holder, to which 2 to 20 times the mass of a solvent is added, and 0 ° C. Extraction is carried out under any conditions such as standing, shaking, stirring, reflux and the like in the range of reflux temperature of the solvent for about 1 minute to 12 hours. After the extraction operation, solid-liquid separation operation such as filtration and centrifugation is performed to remove insoluble solids. The liquid layer is subjected to operations such as dilution and concentration as necessary to obtain an extract. Furthermore, the same operation may be repeated to extract the separated insoluble matter, and the extract may be used in combination with the previous extract. These extracts may be further purified and used according to the purification method commonly used by those skilled in the art. The obtained extract can be used as it is, for example, in the form of a liquid, a concentrate, a dried product obtained by drying these, or the like as it is or by concentration or the like. Drying is not particularly limited, and may be carried out by methods commonly used by those skilled in the art, such as spray drying, lyophilization, reduced pressure drying or fluid drying. Furthermore, it is possible to use what was obtained by pulverizing the dried material obtained by the above-mentioned method using methods known to those skilled in the art as ketchmee in the present disclosure.
Although the content of ketchumishi to the whole composition of the present invention is not particularly limited as long as the effects of the present invention are not impaired, it is usually 0.1 to 99% by mass, preferably 1 to 90% by mass, particularly preferably It is 1 to 70% by mass. The daily dose as ketchmeis is usually 0.1 to 10 g, preferably 0.2 to 2 g, particularly preferably 0.2 to 1.5 g.

Composition-Containing Component 3: Probiotics The probiotics used in the present invention is preferably at least one selected from the group consisting of bifidobacteria, lactic acid bacteria, glycated bacteria, butyric acid bacteria and yeast, for example.

  As preferable probiotics in the present invention, specifically, for example, Bifidobacterium bifidum (eg, Bifidobacterium bifidum G9-1), B. longum, B. breve, B. adolescentis, B. infantis, B. pseudolongum, B. thermophilum etc. For example, Lactobacillus acidophilus, L. casei, L. gasseri, L. plantarum, L. delbrueckii subsp bulgaricus, L. delbrueckii subsp. Lactis, L. fermentum, L. helveticus, L. johnsonii, L. paracasei subsp. paracasei, L. reuteri, L. rhamnosus, L. salivarius, L. brevis and other lactobacilli; Enterococcus) hirae, Streptococcus thermophilus, Lactococcus lactis, L. cremoris, Tetragenococcus halophilus, Pediococcus acidilactici, P. pentosaceus, L. lactis such as Oenococcus oeni etc., for example, Bacillus subtilis, Bacillus mesium B. saccharifying bacteria such as B. sentericus, Bacillus polyfermenticus; For example, sporicidal lactic acid bacteria such as Bacillus coagulans; Butyrate bacteria such as licheniformis, Clostridium butyricum, etc .; and other useful bacteria. In the present invention, it is preferable to use at least one type of bacteria selected from the group consisting of such bifidobacteria, lactic acid bacteria, glycated bacteria and butyric acid bacteria. Among them, use of lactic acid bacteria and / or bifidobacteria is more preferable in that the superior effects of the present invention can be exhibited.

  These bacteria have, for example, morphological characteristics (for example, shape of colony, shape of cell, etc.), physiology, biochemical properties (for example, assimilability of sugar, growth temperature, optimum pH, etc.), chemical taxonomical Properties such as properties (cell fatty acid composition, etc.) may be compared with specific enteric useful bacteria known, and may be bacteria identified based on the comparison results of the properties, based on analysis of the nucleotide sequence of the 16S rRNA gene It may be the identified bacteria or the like. The fungi may be used alone or in combination of two or more. The blending ratio in the case of using two or more kinds of bacteria in combination is not particularly limited.

  These bacteria can be easily obtained, for example, from an organization such as ATCC (registered trademark) or IFO, the Japan Bifidobacterium Center, the National Institute of Technology and Evaluation, Patent Microorganisms Depositary, and the like. Moreover, what is marketed can also be used suitably.

  The above bacteria can be obtained by culturing under known conditions or conditions equivalent thereto. For example, in the case of bifidobacteria or lactic acid bacteria, one or two or more of the above bifidobacteria and lactic acid bacteria are generally used in a liquid medium containing glucose, yeast extract, peptone and the like at a temperature of about 25 to 45 ° C. After aerobic or anaerobic culture for about 72 hours, cells are collected from the culture solution to obtain wet cells. In addition, in the case of glycated bacteria, one or two types of agar medium containing meat extract, casein peptone, sodium chloride and the like are generally cultured aerobically for about 4 to 72 hours at about 25 to 45 ° C. The cells are collected from the culture medium to obtain wet cells.

  In the present invention, in general, a dried product (dried product of dried cells) obtained by subjecting the above-mentioned viable fungi to dry processing is blended. Cell dry matter usually refers to dried individual cells or a collection of dried cells. Drying treatment of viable bacteria can be performed by a conventional method, for example, heat drying, lyophilization, spray drying and the like. In order to obtain the dry matter of the cells, the cells are suspended in a neutral buffer solution to which a suitable stabilizer such as monosodium glutamate, adonitol and the like is added, and dried by a known method or a method known per se. You can also.

In the present invention, it is preferable to use powdered dry matter of the bacterial cell or single micron dry matter as a probiotic. The single micron refers to a range in which the dry matter of the cells is 1 to 10 μm by rounding off the first decimal place. When at least one type of bacteria selected from the group consisting of bifidobacteria, lactic acid bacteria, saccharifying bacteria, butyric acid bacteria and yeast used in the present invention, the viable cell ratio in the preparation obtained using a single-micron dry cell material Is preferable because it improves.
When probiotics are powders prepared by diluting bacteria to a fixed number (about 10 ⁶ to 10 ¹² CFU / g), the content of probiotics to the whole composition of the present invention is the effect of the present invention Although it does not specifically limit as long as it does not prevent, Usually, it is 0.1-30 mass%, Preferably it is 1-25 mass%, Especially preferably, it is 1-10 mass%. In addition, it is preferable that the viable count of probiotics to the whole composition of the present invention is about 10 ⁴ to 10 ¹¹ CFU / g. More preferably, the viable count for the entire composition is about 10 ⁵ to 10 ⁹ CFU / g.

Mass ratio The mass ratio of the antifoaming agent to the ketsumeishi (defoaming agent: ketsumeishi) may be 1: (1 to 15) or may be 1: (1 to 10).
The mass ratio of Ketchmeishi to probiotics (Ketsumeishi: probiotics) may be 1: (0.01 to 1.0) or may be 1: (0.05 to 0.5) .
The mass ratio of probiotics to antifoaming agent (probiotics: antifoaming agent) may be 1: (2 to 4) or 1: (2.5 to 3.5) .
The weight ratio of the antifoaming agent, Ketchmexii and probiotics (defoaming agent: Kewmexii: probiotics) may be 1: (1.0 to 15): (0.25 to 0.5), 1: (1.0 to 10): (0.3 to 0.4) may be sufficient.
The ketchmee may be a crude drug, and may be, for example, an extract powder concentrated 5.9 times. The probiotics are preferably powders prepared by diluting bacteria to a fixed number (about 10 ⁶ to 10 ¹² CFU / g).
If it is in the said range, the composition for abdominal bloating feeling improvement more excellent can be provided.

Composition-Containing Component 4: Others The composition of the present invention may contain components other than the above-mentioned antifoaming agent, Kew Mei and probiotics as long as the effects of the present invention are not impaired.

Method of use (oral administration)
The composition of the present invention may be used in the fields of food and drink, food and drink additives, feed, medicines, quasi drugs and the like.
The compositions of the invention can be administered orally to animals. The dosage form of the oral preparation includes granules, powders, tablets (including coated tablets), pills, capsules, solutions, syrups, emulsions, suspensions and the like.
The composition of the present invention can be formulated using other additives generally used in the fields of food and drink, food and drink additives, feed, pharmaceuticals, and quasi drugs. As such additives, for example, thickeners, enzymes, seasonings, enhancers, manufacturing agents, coloring agents, sweeteners, bittering agents, acidulants, gum bases, brighteners, antioxidants, preservatives, emulsifiers Emulsification stabilizer, Emulsification aid, Germicide, Bleaching agent, Coloring agent, Flavor, Antifungal agent, Extraction solvent, Tofu coagulant, Coating agent, Flour treatment agent, Yeast food, pH adjuster, pH buffer, Swelling agents, nutrient fortifying agents, preservatives, excipients (lactose, mannitol, glucose, microcrystalline cellulose or starch etc.), disintegrants (such as calcium cellulose glycolate), lubricants (magnesium stearate etc.), Coating agents (such as sucrose, gelatin, hydroxypropyl cellulose, or hydroxypropyl methylcellulose phthalate), stabilizers, flavoring agents, solubilizers (glutamic acid, or Buffer, suspending agent, flavoring agent, thickener, astringent, nano-ized substance, preservative, surfactant, sequestering agent, oil, protecting agent, moisturizer, detergent, Anti-inflammatory agent, antibacterial agent, film agent, film remover, emollient agent, plasticizer, vitamin agent, texture improver, stabilizer, fat additive, lubricant, solubilizer, reducing agent, oxidizing agent, base, diluent , Foaming agent, adsorbent, binder (hydroxypropylcellulose, polyvinylpyrrolidone, or magnesium aluminometasilicate etc), gelling agent, conditioning agent, cell activator, softener, penetrant, shaping improver, molding agent Film-forming agents, antistatic agents, neutralizing agents, water-repellent agents, foaming agents, adhesive agents, dispersing agents, sprays, modifiers, water-holding agents, retention agents, solubilizers, solvents and the like. Since these additives are well established in the prior art, the present invention may also follow those prior known techniques.

  The food and drink include functional indication food, food for specified health use, health food, supplement or food for the sick. The form of the food and drink is not particularly limited, but may be a processed form such as a natural liquid food, a semi-digestive nutritional food or a component nutritional food, or a drink, for example. Examples of forms of food and drink include tea beverages, soft drinks, carbonated drinks, nutritional drinks, fruit drinks, lactic drinks, fermented drinks, beverages such as alcoholic beverages, buckwheat noodles such as udon, Chinese noodles, instant noodles, candy, candy , Gum, chocolate, snack foods, biscuits, jellies, jams, creams, baked goods, pastries such as bread, breads, fish and fish products such as kamabo, ham, sausages, dairy products such as processed milk and fermented milk, salad oil , Tempura oil, margarine, mayonnaise, shortening, whipped cream, dressings and other fats and oils and processed foods, sauces, seasonings such as sauces, curry, stew, chopsticks, porridge, risotto etc. retort pouch food, ice cream, sorbet Or frozen desserts such as shaved ice, processed eggs, and the like. In addition, it includes functional display food, food for specified health use, supplement or nutritional supplement, etc., in which the concept of abdominal distension improvement effect is displayed. The said food-drinks can be manufactured according to the manufacturing method of a general food-drinks including the process of adding the composition of this invention in food-drinks.

  The form of the food and drink additive is not particularly limited, and examples thereof include powder, flake, liquid, paste, and granules. The said food-drinks additive can be manufactured according to the manufacturing method of a general food-drinks additive including the process of adding the composition of this invention in a food-drinks additive.

  Examples of feeds include cattle, horses, pigs, sheep, goats, llamas, alpacas, camels, rabbits, minks, foxes, chinchillas, geese, livestock such as geese, chickens and ducks, or guinea pigs, hamsters, mice, dogs, There may be mentioned pets such as cats, monkeys or chimpanzees or animal feed for laboratory animals. The said feed can be processed and manufactured according to the manufacturing method of a common feed including the process of adding the composition of this invention in feed.

  The pharmaceutical or quasi-drug can be implemented in the form of a solid preparation for oral use (tablet, pill, capsule, powder, granules, etc.), a liquid preparation for oral use, or the like. These formulations can be formulated in the same manner as described above.

  An animal to which the composition of the present invention is to be administered is not particularly limited, and may be, for example, a human or a non-human animal. Examples of non-human animals include, but are not limited to, cattle, horses, pigs, sheep, goats, llamas, alpacas, camels, rabbits, minks, foxes, chinchillas, geese, chickens, ducks, guinea pigs, hamsters, mice, rats, Examples thereof include dogs, cats, monkeys and chimpanzees.

Effect (Improvement of abdominal fullness)
In the in vivo test, when the sample is administered to an animal model exhibiting abdominal distension, and the amount of gas and / or intestinal volume in the intestinal tract of the administration group is reduced as compared to the non-administration group, abdominal distension sensation is improved. It can be judged. In addition, with regard to the presence or absence of the abdominal bloating improving effect, for example, the abdominal bloating improving action when a significant difference or a significant tendency is found in the test item “abdomen bloating feeling improvement” as a result of the VAS questionnaire before and after sample administration. It can be judged that there is. The test or evaluation method for that purpose is performed according to a conventional method.

2. Feed The present disclosure contains (1) cellulose, (2) polysaccharides having two or more monosaccharides (excluding cellulose), and (3) an amylase inhibitor or an α-glucosidase inhibitor, and the component (2) And a feed containing a high concentration of (hereinafter also referred to as the feed of the present invention).

(1) Cellulose Cellulose is a polysaccharide in which glucose is β-1,4-glucosidically linked, and is represented by (C ₆ H ₁₀ O ₅ ) n. Since cellulose is commercially available, it can be obtained by purchasing a commercially available product. Examples of the cellulose include crystalline cellulose, hydroxypropyl cellulose, alpha cellulose and the like.
The content of cellulose is not particularly limited as long as the effects of the present invention are not impaired, but it is usually 0.1 to 50% by mass, preferably 1 to 30% by mass, based on the whole feed of the present invention. Is 2 to 20% by mass.

(2) Polysaccharides having two or more monosaccharides (except for cellulose)
The polysaccharides having two or more monosaccharides in the feed of the present invention include disaccharides other than cellulose, oligosaccharides having about 3 to 10 sugars, or polysaccharides. Examples of disaccharides include maltose (malt sugar), sucrose (sucrose), or lactose (lactose). Oligosaccharides include, for example, raffinose, panose, maltotriose, melezitose, gentianose, stachyose, cyclodextrin, fructooligosaccharides, galactooligosaccharides or mannan oligosaccharides. Examples of polysaccharides include starch (amylose and amylopectin), glycogen, chitin, agarose, carrageenan, heparin, hyaluronic acid, pectin and xyloglucan. Among them, starch (amylose, amylopectin) is preferred. Among the starches, corn starch is preferred.
These may be used singly or in combination of two or more. A commercial item can also be used for these.
The content of polysaccharides (excluding cellulose) having two or more monosaccharides is not particularly limited as long as the effects of the present invention are not impaired, but is usually 10 to 90% by mass with respect to the entire feed of the present invention It is preferably 30 to 80% by mass, particularly preferably 40 to 70% by mass.

(3) Amylase inhibitor or alpha-glucosidase inhibitor As an amylase inhibitor or alpha-glucosidase inhibitor, voglibose, acarbose, miglitol etc. are mentioned, for example.
These may be used singly or in combination of two or more. A commercial item can also be used for these.
The content of the amylase inhibitor or the α-glucosidase inhibitor is not particularly limited as long as the effects of the present invention are not impaired, but is usually 0.001 to 0.1% by mass with respect to the entire feed of the present invention. It is 0.005 to 0.05% by mass, particularly preferably 0.005 to 0.015% by mass.

Production method The feed containing any of the above components (1) to (3) is mixed with any of the above components (1) to (3) not contained in the feed, or the above components (1) to (3) The feed of the present invention can be produced by mixing (3) and, if necessary, ingredients (for example, proteins, lipids, minerals, vitamins, etc.) usually contained in the feed.

3. Experimental Animal The present disclosure includes an experimental animal (hereinafter, also referred to as an experimental animal of the present invention) which has received the feed of the present invention.
The experimental animal of the present invention can be produced, for example, by obtaining the experimental animal by a usual method and feeding the feed of the present invention orally to the animal. More specifically, for example, it is prepared by allowing the laboratory animal to orally or forcefully feed the feed of the present invention for about 3 to 21 days, more preferably for about 7 to 14 days. During this time, experimental animals may be allowed free access to water.
The types of experimental animals include mice, guinea pigs, rats, rabbits, dogs, monkeys, chimpanzees and the like.
The daily feed intake of experimental animals is, for example, usually 10 to 20 g in the case of rats.

4. Screening method The present disclosure provides a substance or composition having an abdominal bloating improving action, which comprises the step of measuring the amount of gas and / or intestinal volume in the intestinal tract of an experimental animal of the present invention to which a test substance or composition has been administered. It includes a method of screening (hereinafter also referred to as the screening method of the present invention).

Test substance or composition The test substance or composition may be any substance or composition which the experimenter thinks that it may have an abdominal bloating improving action, and in fact, it has no substance or composition having no abdominal bloating improving action. It may be a thing.

Method of administering a test substance or composition As a method of administering a test substance or composition, for example, oral administration by feeding; gavage oral administration; subcutaneous injection, intradermal injection, intraperitoneal administration, parenteral administration such as tail vein injection, etc. Oral administration by feeding and oral administration by gavage may be combined.

Method of measuring the amount of gas in the intestinal tract Ligate and remove both ends of the intestine of the experimental animal, dip the intestine in a beaker filled with a fixed amount of water, cut it out in water, and collect the released gas Intestinal gas volume (volume) can be measured. Specifically, for example, place a funnel at the opening of a 10 mL measuring flask, remove all the air in the measuring flask in water, invert the measuring flask and funnel so that air does not enter, and remove the excised intestine in water The gas released by dissection can be collected into a measuring flask through a funnel to measure the amount (volume) of intestinal gas. The intestine includes, for example, cecum, ileum, ascending colon, transverse colon, descending colon, sigmoid colon, rectum sigmoid, upper rectum, lower rectum, or a combination thereof, but the cecum exhibits symptoms of abdominal distension. It is preferable in that the increase in the intestinal tract volume which can be performed and the storage of the gas which is the cause of the abdominal distension can be notably confirmed. If the amount (volume) of gas in the intestinal tract of the test substance or composition administration group is smaller compared to that of the test substance or composition non administration group, the test substance or composition is judged to have an abdominal bloating improving action can do.

Method of measuring intestinal volume Ligate and remove both ends of the intestine of the experimental animal, dip the intestine into a beaker filled with water to fill the water, measure the water leakage mass as the intestinal volume, and measure the intestinal volume (cm ³ / experiment It can be calculated as the relative volume of the intestinal tract in terms of the weight of the animal 100 g). The intestine includes, for example, cecum, ileum, ascending colon, transverse colon, descending colon, sigmoid colon, rectum sigmoid, upper rectum, lower rectum, or a combination thereof, but the cecum exhibits symptoms of abdominal distension. It is preferable in that the increase in the intestinal tract volume which can be performed and the storage of the gas which is the cause of the abdominal distension can be notably confirmed.
When the intestinal tract volume of the test substance or composition administration group is smaller than that of the test substance or composition non administration group, it can be judged that the test substance or composition has an abdominal fullness improving effect.

  The present invention includes embodiments in which the above-described configurations are variously combined within the technical scope of the present invention as long as the effects of the present invention can be obtained.

EXAMPLES The present invention will next be described in more detail by way of examples, which should not be construed as limiting the present invention in any way, and many modifications may be made within the technical scope of the present invention. It is possible by the person of ordinary knowledge.
"%" In this example means "mass%" unless otherwise specified.

1. Test Drugs and Reagents As test drugs, dimethicone (dimethylpolysiloxane), dry extract of Ketsumeishi extract (trade name Ketsumeishi extract; manufactured by Kojo Pharmaceutical Co., Ltd .; hereinafter simply referred to as Ketsumeishi), probiotics (Bifidobacterium bifidum G9-1 (Biofermin Pharmaceutical Co.) Dry cells of Streptococcus faecalis 129 BIO 3B (manufactured by Biofermin Pharmaceutical Co., Ltd .; hereinafter referred to as 3B)) were used. In addition, the ketsumeishi extraction dry powder is a 30% ethanol-made dry extract manufactured from JK "Ketsumeishi", and is an extract in which the raw material ketsumeishi is concentrated 5.9 times. That is, the ratio related to the amount of ketsumeishi (the amount of crude drug: the amount of product) is (100: 17). For preparation of a caecal gas production enhanced animal model, high corn starch feed (manufactured by CLEA Japan, Inc.) having the composition shown in Table 1 and acarbose (glucobay tablet 100 mg, Fujifilm Pharma) which is an α-glucosidase inhibitor of component (3) Manufactured by Co., Ltd.).

2. Use animals and breeding conditions Four-week-old Wistar male rats were purchased from Japan SLC, and were subjected to an experiment after 1 week of preliminary breeding.
The animals were reared under an SPF environment at room temperature 22 ± 3 ° C., humidity 55 ± 5% and illumination for 12 hours (7:00 to 19:00). In addition, CE-2 (made by CLEA Japan, Inc.) was freely given as feed, and tap water was freely ingested by a water supply bottle.

3. Test method 1) Preparation of cecal gas production enhancement model 100 mg of Glucobay tablet is ground according to a conventional method, and this is mixed with a high corn starch feed having the composition shown in Table 1 above to obtain a high corn starch feed containing 0.01% by mass acarbose ( (54.7% by mass of corn starch, containing 5.0% by mass of crystalline cellulose) was prepared, and was freely fed to rats for 7 days as feed. In the normal group of rats, high corn starch feed having the composition shown in the above Table 1 was freely fed as feed for 7 days.

2) Drug administration (1) Antifoaming agent alone administration group Dimethicone was suspended in phosphate buffered saline so as to be 3.0 mg / 2.5 mL / kg, and orally administered orally once daily for 7 days .
(2) Ketsumeishi alone administration group The Ketsumeishi was suspended in phosphate buffered saline so as to be 5.8 mg / 2.5 mL / kg, and orally administered orally once daily for 7 days.
(3) Probiotics alone administration group A diet containing 0.01% acarbose-containing high corn starch diet and dried cells of G9-1 and 3B each mixed at approximately 3 × 10 ⁸ CFU / g each for 7 days I had it ingested.
(4) Combined administration group: Dimethicone and Kewmeishi were suspended in phosphate buffered saline to be 3.0 mg / kg and 5.8 mg / kg, respectively, and orally administered orally for 7 days, and 0.01% acarbose The feed was mixed for 7 days in which the high corn starch feed contained was mixed with the dried cells of G9-1 and 3B to give about 3 × 10 ⁸ CFU / g each. Five hours after the final oral administration of the drug, both ends of the cecum were ligated and excised, and the cecal volume and the cecal gas volume were measured.
(5) Control group The above-described cecal gas production model animal with increased gas production was used as a control group to which no drug was administered.

3) Measurement Method of Cecal Volume and Cecal Gas Volume In order to evaluate the degree of abdominal distension, the junction between the cecum and ileum and colon was ligated with a suture, and the cecum was excised. The cecum is submerged in a 100 mL beaker filled with water, and the weight of leaked water is measured as the cecal volume, and the cecal volume per 100 g of rat weight is derived from the cecum volume and the rat weight, and the cecum is relative The volume (cm ³ / body weight 100 g) was calculated. Furthermore, the cecum was dissected in water and the released gas was collected to measure the cecal gas volume. More specifically, place a funnel at the opening of a 10 mL volumetric flask, remove all air in the volumetric flask from water, invert the volumetric flask and funnel to prevent air from entering, and remove the removed cecum in water The gas released by dissection was collected in a measuring flask through a funnel to measure the amount (volume) of cecal gas.

4. Test results 1) Measurement results of cecal gas volume and cecal relative volume in the cecal gas production enhancement model When rats were allowed to freely take 0.01% acarbose-containing high corn starch diet for 7 days, the cecal was compared with the normal group. Significant increases in internal gas volume (Figure 1) and cecal relative volume (Figure 2) were noted. Therefore, this model was used as a cecal gas production enhancement model.
In addition, as a result of conducting the same test as a result of conducting the same test with the feed except crystal cellulose in the above-mentioned 0.01% acarbose-containing high corn starch feed, a decrease in fecal output is recognized, and a large amount of feces remain in the intestine. The volume of gas is small, and it is considered to be unsuitable as a cecal gas production enhancement model.

2) Effects of antifoaming agent, Kewmei, and probiotics on cecal gas volume and cecal relative volume in the caecal gas production model: Antifoaming agent for cecal gas volume and cecal relative volume in the cecal gas production model, Ketmeishi The results of measuring the effect of probiotics alone or the effect of the combination thereof are shown in Table 2 and FIGS. In these charts, “% of control group” means the ratio of each group when the control group is 100%. When acarbose was fed to a high corn starch diet, an increase in cecal gas volume and cecal relative volume was observed (corresponding to the control group in FIGS. 3-10). On the other hand, no significant suppression of the increase in cecal gas volume and cecal relative volume was observed by administering each of the antifoaming agent and Kewtsumeshi alone (FIGS. 3, 4, 7 and 8). Administration of probiotics alone resulted in significant suppression of increase in cecal gas volume (FIG. 5), but no significant suppression of increase in cecal relative volume (FIG. 9). On the other hand, co-administration of all these components significantly suppressed the increase in cecal gas volume (FIG. 6) and cecal relative volume (FIG. 10). Furthermore, as shown below, the actual value of the combined administration group (caecal gas: 67.58, cecal volume: 27.95) became a value larger than the theoretical value in the Colby's equation, so the antifoaming agent, Ketsumeishi It was shown that the combined administration of and probiotics synergistically suppress the increase in cecal gas volume and cecal relative volume in the cecal gas production model.
There was no difference in food consumption for each group.

If the value is larger than the theoretical value calculated by the following Colby's equation, it is judged that there is a synergetic effect.
Colby's formula (3 types)
Theoretical value = (A + B + C)-(AB + AC + BC) / 100 + (ABC) / 10000

  Antifoaming agents, compositions for oral administration containing ketchmexii and probiotics, and methods of screening for substances or compositions having such an effect of improving abdominal bloating, which can improve abdominal bloating are drugs and foods and drinks. It is useful in the field of goods.

Claims (6)

  Composition for oral administration containing an antifoaming agent, ketchmex and probiotics.   The composition according to claim 1, wherein the probiotics are lactic acid bacteria and / or bifidobacteria.   The composition according to claim 1 or 2, which is used for improving abdominal fullness.   (1) cellulose, (2) polysaccharides having two or more monosaccharides (except for cellulose), and (3) amylase inhibitor or α-glucosidase inhibitor, containing component (2) in high concentration Feed.   The experimental animal which ingested the feed of Claim 4.   Administering a test substance or composition to the experimental animal according to claim 5, and measuring the amount of gas and / or intestinal volume in the intestinal tract of the experimental animal to which the test substance or composition has been administered And a method of screening a substance or a composition having an abdominal fullness improving action.